Istodax (Romidepsin) for Myeloma

Overview
Istodax is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat cutaneous T-cell lymphoma in people who have already received at least one systemic therapy. Istodax is sometimes prescribed off-label to treat multiple myeloma. Istodax is also known by its drug name, romidepsin.

Istodax is used as a chemotherapy for multiple myeloma. It is a member of a class of drugs called histone deacetylase inhibitors. Istodax is believed to work by stopping the growth of cancer cells, causing cell death.

How do I take it?
Prescribing information states that Istodax is given as an intravenous infusion (slow injection into your vein) by a healthcare professional. Istodax is usually given in a health clinic or doctor’s office. It should be administered according to the frequency specified by the physician.

Istodax is available only as an intravenous infusion. It should be administered exactly as prescribed by a physician.

Side effects
The FDA-approved label for Istodax lists common side effects including nausea, fatigue, infections, vomiting, and loss of appetite.

Rare but serious side effects listed for Istodax include low blood cell counts and abnormal heart rhythms.

For more details about this treatment, visit:

Istodax — Chemocare
http://chemocare.com/chemotherapy/drug-info/ist...

Patient Information: Istodax — Celgene
https://packageinserts.bms.com/ppi/ppi_istodax.pdf